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INTRODUCTION
Epilepsy is the fourth most common 
neurological disorder and affects more 
than 65 million individuals worldwide.1
This condition is marked by the presence 
of epileptic seizures, which result from an 
abnormal synchronous fi ring of excitatory 
neurons in the brain.1,2 When neurons fi re 
synchronously, a wave of depolarization 
known as a paroxysmal depolarizing shift 
occurs.2 During this period, the neurons 
experience a lowered resistance to fi ring, 
leading to multiple action potentials that 
generate abnormally increased electrical 
activity within the brain.
There are various types of epilepsy 
syndromes that are defi ned based on a 
combination of symptoms. While general-
ized seizures begin in both hemispheres 
of the brain, partial-onset seizures (POS) 
(also called focal or localized seizures) 
and other forms of epilepsy originate in 
only one hemisphere. Patients presenting 
with new-onset seizures must be carefully 
evaluated to determine if the seizures are 
secondary to non-neurological causes; 
differential diagnoses may include hypo-
glycemia, alcohol withdrawal, or electro-
lyte abnormalities. Diagnosis of epilepsy 
involves ruling out these other etiologies 
via laboratory testing, brain imaging, and 
an electroencephalogram. Patients with 
epilepsy may have developed the con-
dition secondary to genetic factors or 
other pathologies, such as brain trauma, 
malignancy, stroke, or neurological 
infection.1,2 While a majority of patients 
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with epilepsy are able to maintain sei-
zure control with one to two antiepileptic 
drugs (AEDs), many individuals require 
adjunctive therapy to achieve long-term 
remission. 
Brivaracetam (Briviact, UCB, Inc.), a 
propyl analogue of levetiracetam, an anti-
convulsant and racetam derivative, was 
granted Food and Drug Administration 
(FDA) approval as an add-on therapy in 
February 2016. It is indicated as adjunc-
tive therapy for treating POS in adults 
and adolescents 16 years of age or older.3
MECHANISM OF ACTION
Brivaracetam is a third-generation 
antiepileptic racetam derivative and a 
4-n-propyl analogue of levetiracetam.1–3
While the exact mechanism of action 
of brivaracetam is unknown, its anti-
convulsant effects are believed to be due 
to its highly selective affi nity for synaptic 
vesicle protein 2A (SV2A) in the brain. 
The SV2A glycoprotein is a protein-
coding gene implicated in synaptic signal 
transduction.4 It is believed to play a role 
in the regulation of neurotransmission 
by stimulating vesicle fusion and main-
taining a reserve of secretory vesicles.4
Studies in SV2A-defi cient animals have 
demonstrated an increased propensity 
for seizures.5 Brivaracetam’s actions as an 
SV2A ligand lend it broad-spectrum activ-
ity against POS. Its chemical structure is 
shown in Figure 1.
PHARMACOKINETICS
Brivaracetam exhibits linear and 
time-independent pharmacokinetics at 
its approved doses. It is freely soluble 
in water, ethanol, methanol, and glacial 
acetic acid.3 The drug experiences near-
complete absorption after oral adminis-
tration and is weakly bound to plasma 
proteins.3 Brivaracetam’s volume of dis-
tribution is 0.5 L/kg, and it is rapidly and 
evenly distributed in most tissues. In addi-
tion, the amide moiety of the drug mol-
ecule undergoes hydrolysis via hepatic 
and extrahepatic amidase to a carboxylic 
acid metabolite.3 This re action is medi-
ated mainly by cytochrome P450 2C19 
(CYP2C19). Genetic poly morphisms 
in CYP2C19 may cause production of 
the metabolite to be decreased. Poor 
metabolizers or patients taking con-
current CYP2C19 inhibitors may require 
dose reduction. Finally, brivaracetam is 
excreted primarily in the urine within 
72 hours of intake.3
CLINICAL TRIALS
The effi cacy of brivaracetam as an 
adjunctive therapy for POS was estab-
lished in several randomized controlled 
trials. Phase 3 trial data follow. (See 
Table 1 for a summary.) 
Ryvlin et al.6
A phase 3, double-blind, randomized, 
placebo-controlled trial conducted across 
88 centers throughout Europe and India 
evaluated brivaracetam versus placebo in 
399 adults with POS. The objective of the 
study was to evaluate the effi cacy, safety, 
and tolerability of brivaracetam versus 
placebo in patients with uncontrolled POS 
despite adequate therapy with one or two 
concomitant AEDs.
Eligible patients were randomized 
to receive brivaracetam 20 mg per day 
(BRV20), 50 mg per day (BRV50), 100 mg 
per day (BRV100), or placebo, admin-
istered twice daily in equal doses. The 
primary endpoint was percent reduction 
in baseline-adjusted POS frequency per 
week over the 12-week treatment period 
Figure 1  Chemical Structure 
Of Brivaracetam3
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versus placebo. Secondary endpoints 
included median percent reduction from 
baseline in POS frequency per week, 50% 
or greater responder rate, and seizure 
freedom from all seizure types.
Ultimately, the study did not meet 
its primary efficacy endpoint. Percent 
reduction in baseline-adjusted POS fre-
quency per week over placebo was 6.8% 
for BRV20 (P = 0.239), 6.5% for BRV50 
(P = 0.261), and 11.7% for BRV100 
(P = 0.019). However, median percent 
reduction from baseline in POS frequency 
per week was 30.0% for BRV20 (P = 0.019), 
26.8% for BRV50 (P = 0.092), and 32.5% for 
BRV100 (P = 0.004), compared with 17% 
for placebo. Adverse events are listed in 
Table 2. The study concluded that while 
the primary efficacy analysis based on 
the BRV50 dose was not statistically sig-
nificant, BRV100 significantly reduced 
POS frequency per week versus placebo. 
Biton et al.7
A phase 3, prospective, multicenter, 
randomized, double-blind, placebo-
controlled, parallel-group, fixed-dose 
trial conducted across 85 centers in 
Australia, Brazil, Canada, Mexico, and 
the U.S. evaluated brivaracetam versus 
placebo in 400 patients. The purpose of 
the study was to evaluate the efficacy, 
safety, and tolerability of brivaracetam 
compared with placebo in patients with 
uncontrolled POS.
Eligible patients were randomized 
to receive BRV5, BRV20, BRV50, or 
placebo, administered twice daily in equal 
doses. The primary endpoint was per-
cent reduction over placebo in baseline-
adjusted POS frequency per week over 
the 12-week treatment period. Secondary 
endpoints included median percent reduc-
tion from baseline in POS frequency per 
week and 50% or greater responder rate.
Percent reduction in POS frequency 
per 28 days over placebo reached sta-
tistical significance for BRV50 (22.0%; 
P = 0.004), but not for the other dose 
groups (BRV5 or BRV20). In addition, 
statistical significance was achieved for 
the 50% or greater responder rate in the 
BRV50 group compared with placebo 
(32.7% versus 16.7%; P = 0.008). BRV50 
also displayed benefits with percent 
reduction in POS frequency from base-
line compared with placebo (30.5% versus 
17.8%; P = 0.003). The study concluded 
that adjunctive therapy with BRV50 offers 
significant reductions in the frequency of 
POS when compared with placebo.
Klein et al.8
A randomized, double-blind, placebo- 
controlled, multicenter trial conducted 
across 147 sites in 27 countries through-
out North America, Europe, Latin 
America, and Asia evaluated brivar-
acetam versus placebo in 768 patients 
with uncontrolled POS despite treatment 
with one or two AEDs. Patients receiv-
ing concomitant levetiracetam were 
excluded. 
Eligible patients were randomized to 
receive BRV100, BRV200, or placebo, 
administered twice daily in equal doses. 
The coprimary efficacy endpoints were 
percent reduction over placebo in 28-day 
adjusted POS frequency and 50% or greater 
responder rate based on percent reduction 
in POS frequency from baseline.
Table 1  A Summary of Phase 3 Trials of Brivaracetam as an Adjunctive Therapy for Partial-Onset Seizures in Adults





























Placebo 100 54 (54.0) 36.4 (13.0) 20.4 (12.3) 17.0
20 mg 99 61 (61.6) 35.7 (12.5) 22.1 (13.6) 30.0 (P = 0.019)
50 mg 99 54 (54.5) 38.9 (13.6) 22.3 (13.0) 26.8 (P = 0.092)
100 mg 100 58 (58.0) 38.0 (13.1) 22.1 (12.8) 32.5 (P = 0.004)












not fully controlled 
despite treatment 
with 1–2 AEDs
Placebo 98 43 (43.9) 37.5 (12.6) 24.3 (12.2) 17.8
5 mg 97 49 (50.5) 38.9 (11.6) 22.2 (12.1) 20.0
20 mg 100 52 (52.0) 37.3 (13.3) 22.9 (14.0) 22.5
50 mg 101 51 (50.5) 38.9 (12.3) 26.2 (12.0) 30.5 (P = 0.003)













Placebo 259 133 (50.9) 39.8 (12.5) 22.7 (13.3) 17.6
100 mg 252 102 (40.3) 39.1 (13.4) 22.2 (13.3) 37.2 (P < 0.001)
200 mg 249 133 (53.2) 39.8 (12.8) 23.4 (14.6) 35.6 (P < 0.001)








Patients with focal 
or generalized 
epilepsy  
un controlled on 
1–3 AEDs
Placebo 121 69 (57.0) 36.5 (11.5) – 18.9
BRV 359 181 (50.4) 35.6 (11.5) – 26.9 (P = 0.070)
AEDs = antiepileptic drugs; BRV = brivaracetam; ITT = intention to treat; POS = partial­onset seizure; SD = standard deviation.
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The study met both of its primary effi-
cacy endpoints. Percent reduction in POS 
frequency per 28 days over placebo was 
22.8% for BRV100 (P < 0.001) and 23.3% 
for BRV200 (P < 0.001). Similarly, the 50% 
or greater responder rate was 21.6% for 
placebo, 38.9% for BRV100 (P < 0.001), 
and 37.8% for BRV200 (P < 0.001).
Treatment-related adverse events 
occurred in 155 of 261 (59.4%) placebo 
patients versus 340 of 503 (67.6%) 
brivaracetam patients. (Table 2) Dis-
continuation rates due to treatment-
related adverse effects were 3.8% for 
placebo, 8.3% for BRV100, and 6.8% 
for BRV200. The study concluded that 
adjunctive therapy with BRV100 and 
BRV200, without the concomitant use of 
levetiracetam, was beneficial in reduc-
ing POS frequency in patients with focal 
seizures, without resulting in significant 
safety or tolerability issues.
Kwan et al.9
A phase 3, double-blind, randomized, 
placebo-controlled, flexible-dose trial 
conducted across 74 sites in 15 coun-
tries throughout Europe and Asia evalu-
ated varying doses of brivaracetam 
versus placebo in 480 patients with 
un controlled epilepsy (431 with POS, 49 
with generalized epilepsy). 
Eligible patients were randomized to 
receive placebo or brivaracetam, admin-
istered twice daily in equal doses. The 
brivaracetam was initiated at BRV20 and 
increased, as needed, to BRV150 during 
an eight-week period. This dose-finding 
period was followed by an eight-week 
fixed-dose maintenance period. The 
primary efficacy endpoint was percent 
reduction in baseline-adjusted POS 
frequency per week.
From October 2007 through December 
2008, 90.0% of BRV-treated patients and 
91.7% of placebo-treated patients com-
pleted the study. Baseline characteris-
tics were largely similar between the two 
treatment groups. The study met its pri-
mary efficacy endpoint. In patients with 
POS, percent reduction in POS frequency 
from baseline was 26.9% for brivaracetam 
versus 18.9% for placebo (P = 0.070). The 
study concluded that adjunctive therapy 
with brivaracetam given at individualized 
doses ranging from 20–150 mg per day 
was well tolerated and effective at reduc-
ing seizure frequency in patients with 
uncontrolled epilepsy.
Summary of Meta-Analyses
Three meta-analyses reviewing 
the efficacy and safety of brivarace-
tam as an adjunctive therapy for POS 
were identified. The first included six 
randomized, placebo-controlled, single- 
or double-blind add-on trials involving 
2,399 patients (1,715 receiving brivar-
acetam and 684 receiving placebo). The 
following endpoints were assessed: 50% 
or greater reduction in seizure frequency, 
seizure freedom, incidence of treatment-
related adverse events, and treatment 
withdrawal. In regard to all of the primary 
endpoints, an x2 test indicated no signifi-
cant statistical heterogeneity between 
the trials. It was determined that 45% of 
levetiracetam-naïve patients responded 
to brivaracetam and 19% to placebo, sug-
gesting a 25% real response rate that was 
not attributable to placebo. Brivaracetam 
was found to be more effective than pla-
cebo in reducing seizure frequency by 
50% or more when added to concomitant 
AEDs in patients with refractory partial 
epilepsy. While there was insufficient 
data to perform a dose–response regres-
sion analysis, the results of the trials 
suggest that a dose-dependent effect 
saturated when the dose of brivarace-
tam reached 50 mg per day. The authors 
concluded that brivaracetam was effec-
tive as an add-on treatment in adults with 
refractory focal epilepsy and may offer 
additional benefits in those patients who 
are levetiracetam-naïve.1
The second meta-analysis included 
five randomized, double-blind, placebo- 
controlled, parallel-group trials that 
assessed the efficacy and safety of bri-
varacetam compared with placebo as 
adjunctive therapy for patients with 
POS. Patients in the trials must have 
received at least one concomitant AED 
at a stable and optimal dosage prior to 
study commencement. Brivaracetam at 
doses of 20, 50, 100, and 150 mg per day 
was associated with significantly higher 
50% responder rates. Brivaracetam 5 mg 
per day was not associated with any sig-
nificant difference in 50% responder rate 
when compared with placebo. In addi-
tion, treatment-related adverse events 
varied depending on the dose. Brivar-
acetam dosed at 150 mg per day was 
more associated with somnolence than 
any other dose. Similarly, fatigue and 
irritability were associated with brivar-
acetam 50 mg per day. In conclusion, it 
was determined that the use of brivarace-
tam at doses greater than 5 mg per day 
resulted in statistically significant reduc-
tions in seizure frequency with respect to 
the 50% responder rate. Brivaracetam was 
mostly well tolerated, with the exception 
of some irritability and somnolence asso-
ciated with the 50-mg and 150-mg per day 
doses, respectively.10
The third meta-analysis included 
five randomized, placebo-controlled, 
single- or double-blind add-on trials 
that investigated the efficacy and 
safety of brivaracetam at varying 
doses. The following endpoints were 
assessed: 50% or greater reduction 
in seizure frequency and seizure- 
free rates. Overall, the 50% responder 
rates of patients receiving brivarace-
tam 20, 50, or 100 mg per day were sig-
nificantly higher than those receiving 
placebo (20 mg: risk ratio [RR] = 1.63, 
P = 0.003; 50 mg: RR = 2.00, P < 0.00001; 
100 mg: RR = 1.80, P = 0.01). In addition, 
patients in all brivaracetam groups expe-
rienced higher seizure-free rates when 
compared with placebo regardless of 
dosage (RR = 4.11, P = 0.01). Patients 
receiving brivaracetam of any dosage 
experienced significantly higher rates 
of adverse effects compared with those 
receiving placebo, specifically somno-
lence (P = 0.02) and fatigue (P = 0.009). 
The authors concluded that brivaracetam 
demonstrated efficacy as an adjunctive 
treatment for refractory POS, as indicated 
by its statistically significant increases in 
the 50% responder rate (P < 0.00001) and 
seizure-free rate (P = 0.01).11 
WARNINGS AND PRECAUTIONS
AEDs may increase the risk of 
suicidal behaviors or thoughts in patients 
taking these medications for any indica-
tion. Patients taking brivaracetam should 
be monitored for depression, suicidal 
ideations, or any unusual changes in 
mood and behavior.3  
Brivaracetam may also cause dose-
dependent increases in somnolence and 
adverse effects such as fatigue, malaise, 
sedation, and lethargy. In the phase 3 
controlled, adjunctive epilepsy trials, 
these adverse effects were seen in 25% 
of patients randomized to receive at least 
50 mg per day of brivaracetam compared 
with 14% of patients receiving placebo.3
Treatment with brivaracetam is associ-
ated with dizziness and disturbances in 
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gait and coordination, such as vertigo, 
ataxia, and nystagmus. In the phase 3 
controlled adjunctive epilepsy trials, these 
adverse reactions were reported in 16% of 
patients randomized to receive at least 
50 mg per day of brivaracetam compared 
with 10% of patients receiving placebo. 
The risk of gait disturbances is greatest 
early in treatment, but may occur at any 
time throughout therapy.3
Brivaracetam is also associated with 
psychiatric adverse events, including 
nonpsychotic symptoms, such as irritabil-
ity, anxiety, aggression, anger, agitation, 
and depression, and psychotic symptoms, 
such as paranoia and acute psychosis. In 
the phase 3 controlled, adjunctive epilepsy 
trials, these adverse reactions were 
reported in 13% of patients randomized 
to receive at least 50 mg per day of bri-
varacetam compared with 8% of patients 
receiving placebo.3
Brivaracetam is also associated with 
hypersensitivity reactions, namely 
broncho spasm and angioedema. The 
medication should be discontinued in 
patients who develop hyper sensitivity 
reactions after being treated with 
brivaracetam.3
DRUG–DRUG INTERACTIONS
Due to the potential for CYP2C19 
induction, coadministration with rifampin 
decreases the plasma concentrations of 
brivaracetam. The dose may need to be 
doubled in patients receiving concomitant 
treatment with rifampin.3
Coadministration with carbamazepine 
may increase exposure to its active metab-
olite, carbamazepine-epoxide. 
While existing data did not reveal 
any safety concerns in patients 
receiving concomitant treatment 
with carbamazepine, the dose of 
carbamazepine may need to be 
reduced if tolerability issues arise 
during therapy.3
Because brivaracetam may 
increase the plasma concentra-
tions of phenytoin, phenytoin 
levels should be monitored 
when brivaracetam is added 








Brivaracetam is in pregnancy 
category C, and there are currently 
no well-controlled studies in pregnant 
women. However, in animal studies, there 
was evidence of developmental toxicity 
at plasma exposures greater than clini-
cal exposures. Therefore, brivaracetam 
should only be used in pregnant patients 
if the potential benefit outweighs the risk 
to the fetus. In addition, pregnant patients 
taking brivaracetam are advised to enroll 
in the North American Antiepileptic Drug 
Pregnancy Registry at 1-888-233-2334 or 
www.aedpregnancyregistry.org. No data 
are available on the excretion of brivar-
acetam in human milk. However, in rat 
studies, it was found that brivaracetam is 
excreted in milk.3 
Pediatric and Geriatric Use
The safety and efficacy of brivarace-
tam has not been established in patients 
younger than 16 years of age. However, in 
juvenile rats and dogs, potential adverse 
effects on postnatal growth and develop-
ment were observed. In addition, in the 
double-blinded, placebo-controlled epi-
lepsy trials, there were too few patients 
ages 65 years or older to assess the medi-
cation’s efficacy. However, dose selection 
for elderly patients should begin at the 
lower end of the dosing range and should 
be made with careful consideration of the 
patient’s hepatic function, renal function, 
and other drug therapy.3 
Renal and Hepatic Impairment
Patients with impaired renal function 
do not require dose adjustments of brivar-
acetam. However, the medication is not 
recommended in patients with end-stage 
renal disease receiving dialysis because 
there are no data in this patient popula-
tion. For patients with any stage of hepatic 
impairment, the recommended starting 
dose of brivaracetam is 25 mg twice daily 
and the recommended maximum dose is 
75 mg twice daily.3
DOSAGE AND ADMINISTRATION
The recommended starting dose for 
brivaracetam is 50 mg twice daily (100 mg 
total daily dose).3 Gradual dose escala-
tion is not necessary when initiating 
treatment. The dosage may be adjusted 
down to 50 mg daily or up to 200 mg daily 
depending on patient tolerability and 
therapeutic response.2 Brivaracetam is 
available as an oral tablet (10 mg, 25 mg, 
50 mg, 75 mg, and 100 mg), oral solution 
(10 mg/mL), and intravenous (IV) injec-
tion (50 mg/mL). If oral administration of 
brivaracetam is not feasible, the injectable 
form may be administered at the same 
dosage and frequency as the tablets and 
oral solution. However, it is important to 
note that the clinical study experience 
with brivaracetam injection is limited to 
four consecutive days of therapy.3
The oral tablets and solution may be 
taken with or without food. Brivarace-
tam tablets should be swallowed whole 
with liquid and not chewed or otherwise 
crushed. The oral solution should be mea-
sured out and delivered with a calibrated 
measuring device in order to accurately 
deliver the prescribed dose. The oral solu-
tion does not need to be diluted and may 
be administered using a nasogastric or 
gastrostomy tube. Any unused brivar-
acetam oral solution should be discarded 
after five months of opening the bottle.3 
Brivaracetam injection is for IV use 
and is single-dose only. The injection 
does not need to be diluted, though it 
may be mixed with the following diluents: 
0.9% sodium chloride injection USP, lac-
tated Ringer’s injection, or 5% dextrose 
injection USP. The injection should be 
administered over two to 15 minutes. If 
diluted, the solution may be stored in 
PVC bags, but must not be stored for 
more than four hours at room tempera-
ture. Generally, the medication may be 
stored at 25°C (77°F), with excursions 
Table 2  Safety Data for Brivaracetam  














N/R = not reported.
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permitted between 15°C to 30°C (59°F 
to 86°F). The injection and oral solution 
formulations should not be frozen.3
COST
Brivaracetam is supplied in three 
formulations: 10-mg, 25-mg, 50-mg, 
75-mg, and 100-mg tablets; 10-mg/mL 
oral solution; and 10-mg/mL injection 
for IV administration.3 The 10-mg tab-
lets are available for dose titration. The 
average wholesale price (AWP) for a 
60-tablet package of all dosages of the 
tablet formulation or for the 300-mL bottle 
of oral solution is $1,092.12 The AWP for a 
package of 10 single-dose 5-mL vials for 
IV administration is $468.12
P&T COMMITTEE  
CONSIDERATIONS
Brivaracetam is an FDA-approved 
medication indicated as adjunctive ther-
apy in patients with POS. Clinical studies 
have evaluated the safety and efficacy of 
brivaracetam in comparison with treat-
ment with placebo and found that bri-
varacetam (dosed 50 mg per day, 100 mg 
per day, or 200 mg per day) demonstrates 
significant reductions in POS frequency 
across all doses (P < 0.01 for all arms). 
Brivaracetam is available in tablet, oral 
solution, and injection formulations with 
a price that is comparable to other FDA-
approved therapies for adjunctive treat-
ment of POS. The oral formulations are 
available with flat pricing; therefore, all 
strengths would likely need to be added 
to a drug formulary.
Despite promising data from clinical 
studies, there is a lack of evidence sug-
gesting that brivaracetam offers any ben-
efit over other AEDs, such as levetirace-
tam. While the available data suggests 
brivaracetam may provide some benefit 
over placebo, this is not sufficient cause 
for it to be included on hospital formu-
laries. Brivaracetam may have a role as 
an adjunctive therapy for patients whose 
epilepsy remains uncontrolled despite 
taking one to two concomitant AEDs.
CONCLUSION
Brivaracetam is a racetam derivative 
and SV2A ligand approved as adjunctive 
therapy for the treatment of POS in adults 
and adolescents 16 years of age and older. 
This medication has shown promise in 
patients with epilepsy whose seizures 
persist despite adequate treatment. 
Brivaracetam was well tolerated through-
out all three phase 3 trials, which led to its 
FDA approval. The drug offers improved 
seizure control with minimal safety risks 
for patients with epilepsy. 
REFERENCES
1. Lattanzi S, Cagnetti C, Foschi N, et al. 
Brivaracetam add-on for refractory focal 
epilepsy: a systematic review and meta-
analysis. Neurology 2016;86(14): 1344–1352.
2. Fisher RS, Acevedo C, Arzimanoglou 
A, et al. ILAE official report: a practical 
clinical definition of epilepsy. Epilepsia 
2014;55(4):475–482.
3. Briviact (brivaracetam) prescribing infor-
mation. Smyrna, Georgia: UCB, Inc.; 2016.
4. Synaptic vesicle glycoprotein 2A gene 
(protein coding). GeneCards Human 
Gene Database. Available at: www.
genecards.org/cgi-bin/carddisp.
pl?gene=SV2A. Accessed May 16, 2016.
5. Kaminski RM, Gillard M, Klitgaard H. 
Targeting SV2A for discovery of anti-
epileptic drugs. In: Noebels JL, Avoli M, 
Rogawski MA, et al., eds. Jasper’s Basic 
Mechanisms of the Epilepsies [Internet], 
4th ed. Bethesda, Maryland: National Cen-
ter for Biotechnology Information (US); 
2012. Available at: www.ncbi.nlm.nih.gov/
books/NBK98183. Accessed May 16, 2016.
6. Ryvlin P, Werhahn KJ, Blaszczyk B, et al. 
Adjunctive brivaracetam in adults with 
uncontrolled focal epilepsy: results from 
a double-blind, randomized, placebo-
controlled trial. Epilepsia 2014;55(1):47–56. 
7. Biton V, Berkovic SF, Abou-Khalil B, 
et al. Brivaracetam as adjunctive treat-
ment for uncontrolled partial epilepsy in 
adults: a phase III randomized, double-
blind, placebo-controlled trial. Epilepsia 
2014;55(1):57–66. 
8. Klein P, Schiemann J, Sperling MR, 
et al. A randomized, double-blind, placebo-
controlled, multicenter, parallel-group 
study to evaluate the efficacy and safety of 
adjunctive brivaracetam in adult patients 
with uncontrolled partial-onset seizures. 
Epilepsia 2015;56(12):1890–1898. doi: 
10.1111/epi.13212. 
9. Kwan P, Trinka E, Van Paesschen W, et al. 
Adjunctive brivaracetam for uncontrolled 
focal and generalized epilepsies: results 
of a phase III, double-blind, randomized, 
placebo-controlled, flexible-dose trial. 
Epilepsia 2014;55(1):38–46.
10. Tian X, Yuan M, Zhou Q, et al. The effi-
cacy and safety of brivaracetam at dif-
ferent doses for partial-onset epilepsy: 
a meta-analysis of placebo-controlled 
studies. Expert Opin Pharmacother 
2015;16(12):1755–1767.
11. Ma J, Huang S, You C, et al. Adjunctive 
brivaracetam for patients with refrac-
tory partial seizures: A meta-analysis of 
randomized placebo-controlled trials. 
Epilepsy Res 2015;114:59–65.
12. Red Book Online. Ann Arbor, Michi-
gan: Truven Health Analytics. Accessed 
December 19, 2016. n
